In this respect, the outcome of ongoing clinical trials with clemizole as an add-on therapy to control drug-resistant convulsive seizures in patients with DS will be important because this antihistamine was identified as a potential novel treatment of this syndrome by a phenotypic screening of drug libraries in zebrafish scn1 mutants [211]. The gene discussed is SCN1A; the disease is Dravet syndrome.